Resuscitation and hemorrhage control
›Immediate stabilization
›IV fluids and blood products
›Packed red blood cells for hemorrhagic shock
›Balanced transfusion strategy per local protocol
›Analgesia
›Acetaminophen
›Opioid titration for severe pain
›Antiemetics
›Ondansetron
›Metoclopramide
›Alloimmunization prevention
›Rh negative and any bleeding or pregnancy loss concern
›Rh(D) immune globulin per local dosing protocol
›Timing within 72 hours when possible
›Documentation
›Rh status result
›Dose and time given
Medical management with methotrexate
›Candidate selection
›Hemodynamic stability
›No evidence of rupture
›No significant free fluid
›Follow up reliability
›Serial beta hCG visits
›Return precautions understanding
›Favorable disease factors
›Low and declining or low plateau beta hCG
›Small ectopic mass size
›Contraindications
›Absolute contraindications
›Hemodynamic instability or suspected rupture
›Breastfeeding
›Immunodeficiency
›Significant hepatic disease
›Hematologic and renal contraindications
›Moderate or severe anemia
›Leukopenia
›Thrombocytopenia
›Significant renal impairment
›Pulmonary and GI contraindications
›Active pulmonary disease
›Peptic ulcer disease
›Single dose regimen
›Methotrexate IM 50 mg per m2
›Day 1 dosing
›Baseline beta hCG and labs
›Monitoring schedule
›Beta hCG day 4
›Beta hCG day 7
›Response criterion
›If day 4 to day 7 decrease < 15 percent, repeat dose or surgical evaluation
›If appropriate decline, weekly beta hCG until negative
›Two dose regimen
›Methotrexate IM 50 mg per m2
›Day 1 dosing
›Day 4 dosing
›Monitoring schedule
›Beta hCG day 4
›Beta hCG day 7
›Response criterion
›If inadequate decline, additional dose or surgery per protocol
›Patient counseling and safety
›Avoid folic acid supplements during treatment
›Reduced methotrexate effectiveness
›Resume after completion per clinician guidance
›Avoid alcohol
›Hepatotoxicity risk
›Dehydration risk
›Avoid NSAIDs if advised by treating team
›Drug interaction concern
›Follow local protocol
›Avoid intercourse and vigorous exercise until resolution
›Rupture risk while healing
›Bleeding risk
›Indications
›Rupture suspicion
›Instability
›Significant free fluid
›Methotrexate failure
›Rising or plateau beta hCG after treatment
›Persistent pain with concern for rupture
›Contraindications to methotrexate
›Organ disease
›Follow up barriers
›Approaches
›Laparoscopy preferred when stable
›Salpingostomy
›Salpingectomy
›Laparotomy for instability
›Rapid hemorrhage control
›Damage control principles
Evidence and recommendations
›Guideline aligned management statements
›Suspected ruptured ectopic pregnancy, immediate surgical management, Class I recommendation
›Maternal life threat
›Delay increases mortality
›Methotrexate appropriate for selected stable patients, Class I recommendation
›Requires reliable follow up
›Shared decision making